Systemic Lupus Erythematosus Cytokines Assay

Introduction

Creative proteomics can provide high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies.

Systemic lupus erythematosus (SLE) is a representative autoimmune disease characterized by a high proliferation of polyclonal B cells, an increase in immunoglobulin, the production of a variety of autoantibodies, and a low intracellular and extracellular immune response. A large number of cytokines, signal molecules and pattern recognition receptors in the immune system participate in the pathological process of the disease. Pro-inflammatory cytokines, like the local inflammatory response that leads to tissue damage, are involved in immune disorders that are common in SLE patients. SLE usually occurs after the immune system's own tolerance collapses. This process involves different systemic inflammatory mediators, such as cytokines, proteases, autoantibodies and cell adhesion receptors. The detection of SLE-related cytokines or proteins can promote the research on the mechanism of disease occurrence and development and related treatment methods.

Cytokines involved in systemic lupus erythematosus

IL-6, IL-10, IL-12, IL-18, IFN-γ have all been suggested that the expression level of SLE will change to varying degrees during the development of SLE. IFN-γ inhibits the differentiation of Th0 to Th2. IL-4 and IL-10 inhibit the differentiation of Th0 to Th1. Cytokines secreted by mononuclear macrophages such as IL-12, IL-18 also have regulatory effects on Th1/Th2 differentiation. The detection of these indicators has certain significance for the evaluation and prognosis of the disease.

B-lymphocyte stimulating (BLyS) factor is a new member of the TNF ligand superfamily. It has strong proliferation, differentiation and antibody secretion effects on B cells, and plays an important role in the pathological process of SLE. The expression level of TGF-β in the serum and urine of SLE patients is abnormal, which may be a potential therapeutic target.

TNF-α is a pleiotropic and multifunctional cytokine in the immune system. It can not only promote the development of autoimmune inflammation, but also slow down the process of inflammation. It is an effective therapeutic target. A variety of therapeutic TNF-α inhibitors have been developed for the treatment of SLE diseases.

Detectable cytokines include but are not limited to:

Technology platform

We mainly provide the Luminex cytokine detection platform. Luminex uses fluorescently encoded microspheres with specific antibodies to different target molecules. The different microspheres can be combined freely to a certain extent so that up to 100 analytes can be tested multiple times simultaneously in a single experiment.

The Luminex cytokine assay platform has the following advantages:

• Multiple detection: simultaneous detection of 100 biological targets
• Short experiment time: 1-3 weeks
• High sensitivity: the lower limit of accurate quantification is as low as 0.1 pg/mL
• Save samples: only need a sample volume as low as 25 μL
• Time saving: the experiment process only takes 4 hours

For your different needs, we can also provide the following detection methods:

• Flow cytometry (FACS analysis): Identify and measure cell biomarkers in complex subpopulations. It can be used for intracellular cytokine detection without two hours.
• Enzyme-linked immunosorbent assay (ELISA): Use the primary antibody for capture, and conjugate the secondary antibody with an enzyme or radioisotope for detection. Our multiplexing system can detect the expression of multiple cytokines at once.

Sample preparation

• Suitable for serum, plasma, cell culture supernatant and all kinds of body fluids.
• Cells (whole blood cells, PBMC, mouse immune cells)
• The body fluid samples are stored in a refrigerator at -80 degrees Celsius and transported on dry ice.

Creative Proteomics can provide you with a one-stop solution. If you want to test other cytokines or other information you want to consult, please contact us. We are looking forward to cooperating with you.

Reference:

1. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. Journal of Biomedicine and Biotechnology, 2011, 2011.